Corona: India Biotech launches nasal vaccine trial, 10 shortlisted

- Only one drop of Coro-Flu manufactured by Bharat Biotech will work

New delhi date. Friday, March 5, 2021

The mission is now a further success as vaccination against the corona virus continues in the country. Hyderabad-based Bharat Biotech has started trials of the nasal vaccine. It involves administering a dose of the vaccine through the nose, which may be effective against corona.

Bharat Biotech had earlier this year sought approval for a phase-1 trial which was approved by the Drug Controller General of India. The trial of intranasal vaccine (BBV154) was started at a hospital in Hyderabad earlier this week. Ten people have been shortlisted for the trial while two have been vaccinated. According to Bharat Biotech, the two people who have been vaccinated are perfectly healthy.

If the trial of the nasal vaccine is completely successful and it is approved, it will be very effective in preventing the risk of corona virus. This vaccine is more likely to be effective as it is given through the nose. With just one drop of Coro-Flu manufactured by Bharat Biotech, the work will be done.

India Biotech has developed it in collaboration with the University of Washington through research on the Nasal vaccine. It is learned that no needle of any kind is required to give this vaccine. It also does not require any kind of trained health worker.

5 Benefits of Nasal Vaccine:

1. Get rid of the injection

2. Immune readiness in the inner part of the nose will reduce the risk of respiratory infections

3. Health workers do not need training to get rid of injections

4. Vaccination facility is also possible for children due to low risk

5. Production and supply possible as per demand all over the world as production is easy

Two vaccines are currently approved in India. CoveShield of Serum Institute of India, Covexin of Bharat Biotech is currently providing the vaccine. Both vaccines are given in two doses with an interval of 28 days.